Abstract: The present invention pertains to the field of pharmaceutical chemistry, and relates to compounds having cyclopentanoperhydrophenanthrene skeletons and preparation methods therefore. The compounds have some physiological activity, and are useful as synthons/intermediates for further synthesizing some compounds having specific structures. These compounds and salts thereof are useful as lead compounds for synthesizing pharmaceuticals, pesticides and new materials. From this, further screen and preparation by chemical, biological and medical means offer new compounds that are more valuable and have important applications, achieving the object of inventing and creating new drugs.

Abstract: A highly effective catalyst for the preparation of diethyl oxalate using carbon monoxide using Pd/?-Al2O3 and CeO2 as a promoter. High conversion rates with greatly extended catalyst life is achieved with the CeO2-enhanced Pd catalysts. The catalysts can be used for the production of high-value diethyl oxalate, and eventually ethylene glycol, from coal-derived syngas.

Abstract: It is intended to provide a method capable of industrially and efficiently producing acetic acid having a good potassium permanganate test value without a large cost. A method for producing acetic acid according to the present invention is a method for producing acetic acid comprising: a carbonylation reaction step; an evaporation step; a lower boiling point component removal step; and a first overhead stream recycle step of recycling at least a portion of an aqueous phase and/or an organic phase obtained by condensing a first overhead stream obtained in the lower boiling point component removal step to a reaction vessel, wherein a crotonaldehyde concentration in a first acetic acid stream obtained in the lower boiling point component removal step is controlled to not more than 2.2 ppm by mass. The catalyst system may further contain an ionic iodide.

Abstract: Processes for producing propylene glycol are disclosed. The processes may comprise subjecting a polyol to a hydrogenolysis reaction, thus producing propylene glycol and a product stream including an unreacted polyol and at least one unwanted compound. The process may include subjecting the product stream to a process that removes at least a portion of the at least one unwanted compound, thus producing a cleaned product stream, and subjecting the cleaned product stream to the hydrogenolysis reaction. Systems for implementing such processes are also described.

Abstract: The present invention generally relates to a process of preparing iosimenol and a process of preparing a crystal of iosimenol, as well as a crystal of iosimenol prepared by these processes.

Abstract: The present specification relates to a novel compound, and a color conversion film, a backlight unit and a display apparatus including the same.

Abstract: A reaction product containing amido amine groups, comprising one or more species of the general formula (I) (R1—X)p—Z1—(XH)y??(I) where p+y=w and w is an integer from 1 to 10, p is an integer from 1 to 10, y is an integer from 0 to 9, and X is independently O, NH and/or NZ2 and XH is independently a hydroxyl group OH, a primary amino group NH2 and/or a secondary amino group NHZ2 where Z2 is independently a branched or unbranched, saturated or unsaturated organic radical G(U)a where U is independently a hydroxyl group, a primary amino group or a secondary amino group and a is an integer from 0 to 9, where p+y+a?10, and G is a branched or unbranched, saturated or unsaturated organic radical, the p R1 radicals are independently a radical of the general formula (II) Y—O—CO—NH—R2—NH—CO??(II) in which the p Y radicals are independently a branched or unbranched, saturated or unsaturated organic radical which has 1 to 1000 carbon atoms and does not contain any hydroxyl groups, any primary amino groups or any seco

Abstract: The present invention relates to a process for continuous hydrogenation of a nitro compound to the corresponding amine in a liquid reaction mixture comprising the nitro compound in the presence of a supported catalyst which comprises as the active component at least one element from groups 7 to 12 of the periodic table of the elements, wherein the hydrogenation is performed in the presence of at least one salt selected from the group consisting of the salts of the alkali metals, alkaline earth metals and of the rare earth metals and to a supported catalyst for continuous hydrogenation of a nitro compound to the corresponding amine in a liquid reaction mixture comprising the nitro compound which comprises as the active component at least one element from groups 7 to 12 of the periodic table of the elements and one salt of the alkali metals, alkaline earth metals or of the rare earth metals.

Abstract: The invention is directed to a method for the manufacture of bisphenol A, and to bisphenol A/phenol adduct crystals. The method of the invention comprises: a) reacting phenol and acetone in the presence of an acidic catalyst to form a reaction product comprising an initial concentration of bisphenol A and an initial concentration of impurities; b) diluting the reaction product with phenol, water and/or acetone, so as to decrease the impurity concentration to 50% by weight or less of the initial concentration of impurities, and adding bisphenol A to increase the concentration thereof in the reaction product; and thereafter c) crystallising a bisphenol A/phenol adduct from the reaction product to produce a crystallised bisphenol A product.

Abstract: A method of producing a hydrogenation catalyst, for example, a phthalate hydrogenation catalyst, comprising contacting a silica support having a medium pore size of at least about 10 nm with an acid to produce a treated silica support, and depositing a noble metal, preferably ruthenium, on the treated silica support to produce a noble metal-containing silica support, and optionally contacting the noble metal-containing silica support with a chelating agent to form the hydrogenation catalyst; a hydrogenation catalyst prepared by that method; and a method of hydrogenating unsaturated hydrocarbons, such as, phthalates, in which an unsaturated hydrocarbon is contacted with hydrogen gas in the presence of the hydrogenation catalyst of the invention.

Abstract: A method of isomerizing methyl 9-decenoate in a reaction mixture, and forming methyl 8-decenoate, and reacting the methyl 8-decenoate by metathesis to form 1,16-dimethyl 8-hexadecenedioate, and hydrogenating 1,16-dimethyl 8-hexadecenedioate to form 1,16-dimethyl hexadecanedioate. In some embodiments, the 1,16-dimethyl hexadecanedioate can be converted to hexadecanedioic acid.

Abstract: The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula.

Abstract: A process for producing a polycarbonate resin by reacting raw materials of a bifunctional compound and diphenyl carbonate, where the bifunctional compound is an isomer mixture of: a 2,6-derivative of a bifunctional compound of formula (3-a): and a 2,7-derivative of a bifunctional compound of formula (3-b): where R2 in formulae (3-a) and (3-b) is, independently, H, CH3 or C2H5, and where the mixing ratio between the 2,6-derivative and the 2,7-derivative is 30:70 to 70:30.

Abstract: Process for methoxycarbonylation with formic acid and methanol.

Abstract: The invention relates to a process comprising the following process steps: a) introducing an ether having 3 to 30 carbon atoms; b) adding a phosphine ligand and a compound which comprises Pd, or adding a complex comprising Pd and a phosphine ligand; c) adding an alcohol; d) supplying CO; e) heating the reaction mixture, the ether being reacted for form an ester; where the phosphine ligand is a compound of formula (I) where m and n are each independently 0 or 1; R1, R2, R3, R4 are each independently selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl, —(C3-C20)-heteroaryl; at least one of the R1, R2, R3, R4 radicals is a —(C3-C20)-heteroaryl radical; and R1, R2, R3, R4, if they are —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl or —(C3-C20)-heteroaryl, may each independently be substituted by one or more substituents selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —O—(C1-C12)-alkyl, —O—(C

Abstract: The present invention relates to a process for preparing alkyl methacrylates, especially MMA, and methacrylic acid, based on methacrolein, which has been oxidatively esterified in a second process stage. Methacrolein is obtainable in principle from C2 and C4 units. The present process has the advantage that the alkyl methacrylate and methacrylic acid can be obtained in a simple manner, in high yields and high purities, either as a mixture or as isolated product streams. In particular, the process of the invention has the great advantage that especially the ratio of the desired methacrylic acid and alkyl methacrylate, especially MMA, products can be adjusted freely within a wide range and varied by chemical engineering measures and operating parameters.

Abstract: The hydrothermal reaction between bioactive metals (Ca2+, Zn2+, and Mg2+) salts and clinically utilized bisphosphonate (BP) alendronic acid (ALEN) were performed to prepare several bisphosphonate-based biocompatible coordination complexes (pBioCCs). The invention describes the effect of three variables M2+/BP molar ratio, reaction temperature, and pH on the reaction outcomes yields an unprecedented number of crystalline materials of enough crystal quality for structural elucidation. The crystal structure was unveiled by single crystal X-ray diffraction at 100 K and their solid-state properties revealed in tandem with other characterization techniques: thermogravimetry, vibrational spectroscopy, and elemental analysis. The invention provides materials with high structural stability and dissolution properties paving the way for better formulation strategies for alendronic acid (ALEN) through the design of pBioCCs for the treatment of bone-related diseases.

Abstract: Disclosed is a process for preparing (Z)-endoxifen, comprising (i) recrystallizing an input crystalline solid comprising a mixture of (Z)-endoxifen (1) and (E)-endoxifen (2) from a first solvent to provide a first crystalline solid and a first mother liquor, wherein the first mother liquor has a ratio of (1) to (2) at least 1.3 times greater than the ratio in the input crystalline solid (1) and (2); (ii) recrystallizing a solid produced by concentrating the first mother liquor, or by removal of the first solvent from the first mother liquor, from a second solvent to give a second crystalline solid and a second mother liquor; (iii) optionally recrystallizing the second crystalline solid from the second solvent one to five additional times to give a third crystalline solid; wherein the third crystalline solid has a ratio of (Z)-endoxifen (1) to (E)-endoxifen (2) greater than 20:1.

Abstract: The present invention discloses a Y-type discrete polyethylene glycol derivative, which has the advantages of determined molecular weights and the number of chain segments, and can avoid the defect of heterogeneity of a PEG derivative. In addition, the Y-type discrete polyethylene glycol derivative of the present invention may increase the water solubility of the discrete polyethylene glycol, and solve the problem of insufficient water solubility of the discrete polyethylene glycol-modified insoluble drug caused by an increase of the loading capacity.

Abstract: A high yield process of preparation of [1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethy]-cyclohexanol] through potassium salt mediated demethylation of [1-[2-(Dimethyl amino-1-(4-methoxyphenyl) ethyl cyclohexanol] in monoethylene glycol under phase transfer conditions, as well as the preparation of salt of [1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]-cyclohexanol].